Symbravo
Migraine
ApprovedCommercial
Key Facts
About Axsome Therapeutics
Founded in 2012 by Dr. Herriot Tabuteau, Axsome Therapeutics has evolved from a development-stage company to a commercial leader in CNS therapeutics. The company's differentiated approach focuses on novel mechanisms of action for conditions with limited treatment options, resulting in three FDA-approved products and a robust pipeline. With a strong intellectual property portfolio extending through 2040 and multiple Phase 3 programs underway, Axsome is well-positioned to expand its leadership in the CNS therapeutic space.
View full company profileTherapeutic Areas
Other Migraine Drugs
| Drug | Company | Phase |
|---|---|---|
| Emgality (galcanezumab) | Eli Lilly | Approved |
| EVO756 | Evommune | Phase 1 |